References
- Caspi R. Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res 2008;42:41–50
- Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci 2003;44:4845–4852
- Hogan AC, McAvoy CE, Dick AD, Lee RWJ. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114:1000–1006
- Fujita E, Teramura Y, Shiraga T, Yoshioka S, Iwatsubo T, Kawamura A, Kamimura H. Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J Ocul Pharmacol 2008;24:309–319
- Yuan J, Zhai J, Chen J, Ye C, Zhou S. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. J Ocul Pharmacol. 2009;25:345–350
- Oh-I K, Keino H, Goto H, Yamakawa N, Murase K, Usui Y, et al. Intravitreal injection of tacrolimus (FK506) supresses ongoing experimental autoimmune uveoretinitis in rats. Br J Ophthalmol 2007;91:237–242
- Da Silva GR, Silva-Cunha A, Behar-Cohen F, Ayres E, Oréfice RL. Biodegradable polyurethane nanocomposites containing dexamethasone for ocular route. Mat Sci Eng C 2011;31:414–422
- Fialho SL, Rêgo MGB, Siqueira RC, Jorge R, Haddad A, Rodrigues-Junior AL, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res, 2006;31:525–534
- Zidan AS, Rahman Z, Sayeed V, Raw A, Yu L, Khan MA. Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis. Int J Pharm 2012;423:341–350
- Zhang R, He R, Qian J, Guo J, Xue K, Yuan Y. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010;51:3575–3582